BRAF Mutation Analysis in UAE | 1200 AED | 2026 DHA Guidelines

تحليل طفرة BRAF في الإمارات | 1200 درهم | معتمد من هيئة الصحة بدبي

99.9% Diagnostic Sensitivity – ISO 9001:2015‑accredited laboratory processing ensures definitive BRAF mutation identification (V600E and rarer variants) for precision oncology decisions, fully aligned with 2026 DHA molecular testing standards.

ضمان الدقة: حساسية تشخيصية 99.9% عبر معالجة مختبرية معتمدة بمعيار ISO 9001:2015، مما يضمن تحديد طفرات BRAF بدقة لتوجيه العلاج الموجه.

🚀 Premium Logistics: Hospital‑grade cold‑chain home collection (VIP mobile phlebotomy) for FFPE block or whole blood within Dubai/Sharjah/Abu Dhabi, 8 AM‑11 PM.

📞 Clinical Guidance: Free post‑test telephonic interpretation session with our DHA‑licensed molecular oncology advisor.

💳 Insurance: Direct billing verification via WhatsApp at +971 54 548 8731. All major UAE insurers accepted.

Overview | نظرة عامة

يفحص تحليل طفرة BRAF التغيرات الجينية في جين BRAF (أهمها V600E) من عينة نسيجية مثبتة بالفورمالين ومضمنة بالبارافين أو من الدم الكامل. يُستخدم لتوجيه العلاج الموجّه في الأورام مثل الورم الميلانيني وسرطان القولون والمستقيم ويعتبر من الركائز الأساسية للطب الدقيق في الإمارات وفق إرشادات هيئة الصحة بدبي لعام 2026.

The BRAF Mutation Analysis detects clinically actionable somatic mutations (primarily V600E) in solid tumours. It is mandatory for initiating targeted BRAF/MEK inhibitors in melanoma, colorectal carcinoma, and certain thyroid cancers. All testing adheres to DHA 2026 precision oncology protocols, with results validated by orthogonal NGS and real‑time PCR.

Feature	Our BRAF Test	Closest Alternative (Standard Sanger)
Method	Targeted Real‑Time PCR + Next‑Generation Sequencing (NGS) confirmation	Sanger sequencing alone
Sensitivity	99.9% (LOD down to 1% VAF)	~95% (LOD ~15‑20% VAF)
Turnaround	Sample Tue 11 AM → Report Mon	10‑14 days
Reflex Testing	NGS full panel available if V600E negative (no re‑biopsy needed)	Single‑gene, requires new sample for broader profiling

Physician Insight & Safety Protocol | رؤية الطبيب وبروتوكول السلامة

“A BRAF mutation result is never a stand‑alone diagnosis. It must be correlated with histopathology, staging, and clinical presentation. V600E‑positive melanoma patients often respond dramatically to dual blockade, but rare non‑V600E mutations may predict resistance. Discuss every report with a molecular tumour board before altering treatment.”

– Dr. Prabhakar Reddy, DHA License: 61713011, Consultant Molecular Oncologist

⚠️ Medication Warning:

Do not discontinue prescribed medication without consulting your doctor. A positive BRAF result may indicate eligibility for new targeted therapies, but stopping current treatment abruptly can cause tumour flare or serious adverse events. Always coordinate changes with your treating oncologist.

Exclusion Criteria & Emergency Red Flags

Paraffin block with <10% viable tumour cells – sample will be rejected; re‑biopsy advised.
Missing or incomplete NGS Test Requisition (Form 40) – processing halted until submitted.
Specimen frozen or shipped on dry ice for FFPE – invalid; only room‑temperature transport allowed.
Seek emergency care if you develop sudden severe pain, high fever, uncontrolled bleeding, or neurological symptoms while awaiting results.

Patient FAQ & Clinical Guidance | الأسئلة الشائعة والتوجيه السريري

What is the purpose of a BRAF mutation test?

This test identifies acquired BRAF gene mutations (principally V600E) to guide targeted therapy selection for advanced melanoma, colorectal, and non‑small‑cell lung cancers, directly affecting survival and eligibility for kinase inhibitors.

ما الهدف من فحص طفرة BRAF؟ يحدد الطفرات الجينية المكتسبة في جين BRAF (خاصة V600E) لتوجيه العلاج الموجّه في الميلانوما وسرطان القولون.

How should I prepare my sample and what are the requirements?

No fasting or medication changes are needed; however, your FFPE tissue block must contain ≥10% tumour nuclei and be accompanied by a duly filled NGS Requisition (Form 40), else the sample cannot be processed.

هل يلزم صيام؟ لا يلزم صيام أو تغيير الأدوية، لكن يجب أن تحتوي كتلة النسيج المُثبتة على 10% خلايا ورمية على الأقل مع استمارة الطلب (Form 40).

When will I receive my BRAF results and who interprets them?

Samples arriving by Tuesday 11 AM are reported on the following Monday; every result is verified by a DHA‑licensed molecular pathologist and the referring oncologist receives a clinical interpretation summary.

متى تظهر النتائج؟ العينات التي تصل قبل الثلاثاء 11 صباحًا تُصدَر تقاريرها يوم الاثنين التالي، ويفسرها أخصائي علم الأمراض الجزيئي المعتمد من هيئة الصحة.

دعم ثنائي اللغة متاح